DelveInsight’s ‘Essential Thrombocythemia (ET) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Essential Thrombocythemia, historical and forecasted epidemiology as well as the Essential Thrombocythemia trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Essential Thrombocythemia Understanding
According to the MPN Research Foundation, Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by an increased number of platelets in the blood. The overproduction (megakaryocytic hyperplasia) of platelet-forming cells, called “megakaryocytes,” in the marrow results in the release of too many platelets into the blood.
The term “essential” indicates that the increase in platelets is an inherent problem of the blood cell production in the bone marrow and “Thrombocythemia” refers to an excess of platelets in the blood. Also, the increased platelet count may result in the blockage in blood vessels (thrombus), splenomegaly, and hemorrhagic episodes. Most cases of ET are not inherited, and it arises from gene mutations that occur in early blood-forming cells after conception. However, in very rare cases, ET is inherited in an autosomal dominant pattern and known as familial Essential Thrombocythemia.
The typical pattern of ET onset is bimodal, with one peak occurring during young adulthood in females and the other peak occurring between the ages of 50–70 years in both males and females. The incidence of ET is around 1.5–2 times higher in females as compared to males.
Essential Thrombocythemia (ET) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Essential Thrombocythemia (ET), Total Prevalence of Essential Thrombocythemia Based on Symptoms, Gender-specific Diagnosed Prevalence of Essential Thrombocythemia, Age-specific Diagnosed Prevalence of Essential Thrombocythemia, Prevalence of Essential Thrombocythemia based on Risk, and Gene Mutation Specific Prevalence of Essential Thrombocythemia scenario of ET in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Essential Thrombocythemia (ET) Detailed Epidemiology Segmentation
• As per DelveInsight’s analysis, the total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM was found to be 232,688 in 2017. The estimates higher prevalence of Essential Thrombocythemia (ET) in the United States with 142,635 cases in 2017.
• According to DelveInsight’s analysis, it has been observed that ET is mostly diagnosed in the age group of 60-80.
• Among EU5, France shows a higher prevalence of ET followed by Germany and the UK, Italy, and Spain respectively.
• Japan accounts second among the 7MM in terms of prevalent cases with 19,946 cases among the 7MM.
Scope of the Report
• The report covers the descriptive overview of Essential Thrombocythemia (ET), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Essential Thrombocythemia (ET).
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Population of Essential Thrombocythemia (ET), Total Prevalence of Essential Thrombocythemia Based on Symptoms, Gender-specific Diagnosed Prevalence of Essential Thrombocythemia, Age-specific Diagnosed Prevalence of Essential Thrombocythemia, Prevalence of Essential Thrombocythemia based on Risk, and Gene Mutation Specific Prevalence of Essential Thrombocythemia
Report Highlights
• 11-Year Forecast of Essential Thrombocythemia (ET)
• 7MM Coverage
• Total Prevalent Cases of Essential Thrombocythemia (ET),
• Total Prevalent Population of Essential Thrombocythemia (ET) based on Symptoms
• Total Gender-specific Diagnosed Prevalence of Essential Thrombocythemia (ET)
• Total Age-specific Diagnosed Prevalence of Essential Thrombocythemia (ET)
• Total Prevalence of Essential Thrombocythemia (ET) based on Risk
• Gene Mutation Specific Prevalence of Essential Thrombocythemia (ET)
Key Questions Answered
• What is the disease risk, burden and unmet needs of Essential Thrombocythemia (ET)?
• What is the historical Essential Thrombocythemia (ET) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Essential Thrombocythemia (ET) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Essential Thrombocythemia (ET)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Essential Thrombocythemia (ET) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy
The Essential Thrombocythemia (ET) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Essential Thrombocythemia (ET) epidemiology forecast.
• The Essential Thrombocythemia (ET) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Essential Thrombocythemia (ET) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook